Clinical trials · New York
Breast Carcinoma clinical trials in New York
We’re tracking 78 recruiting breast carcinoma studies with a site in New York — including Phase 1, Phase 1/Phase 2, Phase 2 and Phase 3 studies, each written for real people, not researchers.
Recruiting studies in New York
- NCT05334069Recruiting
Blood test study for early cancer detection in patients
This study collects blood from people with cancer and people without cancer (or with possible cancer) to test whether new blood tests can detect cancer earlier. Your blood samples help researchers evaluate how well these tests work.
Elmhurst, New YorkAges 40–75 - NCT05059444Recruiting
Blood test to catch cancer early after treatment
This study looks for signs of cancer left in the body after treatment using a simple blood test (called a liquid biopsy). It aims to see if the test can catch cancer that might come back earlier than regular scans.
New York, New YorkAges 18 years+ - NCT04526587Recruiting
Study of breast cancer markers after CDK4/6 inhibitor treatment
This study looks at lab markers and clinical features in people with certain types of breast cancer who are being treated with, or have already been treated with a CDK4/6 inhibitor like abemaciclib (ciclib-based therapy). It aims to understand patterns that may help doctors better characterize breast cancer after these treatments.
Buffalo, New YorkAges 18 years+ - NCT07723209Recruiting
Radiation after no lymph node sampling in breast cancer
This trial tests whether radiation therapy alone is safe and effective for women 40 and older with early-stage breast cancer who have not had lymph node sampling. It aims to simplify treatment while maintaining good outcomes.
New York, New YorkAges 40 years+ - NCT06418204Recruiting
Cannabis use among cancer patients in community clinics
This study looks at how cancer patients use cannabis (marijuana) and cannabis products to manage symptoms during chemotherapy or immunotherapy. The goal is to learn about the benefits and risks so doctors can better guide patients.
Jamaica, New YorkAges 18 years+ - NCT05812807RecruitingPhase 3
Pembrolizumab versus monitoring after triple-negative breast cancer response
This trial checks whether giving pembrolizumab (an immunotherapy) after surgery helps people with triple-negative breast cancer reduce the chance of the cancer coming back, compared with close monitoring only. It’s for patients who had no remaining invasive cancer after neoadjuvant chemotherapy plus pembrolizumab.
Staten Island, New YorkAges 18 years+ - NCT03418961RecruitingPhase 3
Study of heart-risk management for metastatic HER2 breast cancer
This trial follows people with metastatic HER2-positive breast cancer who are at higher risk for heart damage while on HER2-targeted therapy. Some participants are randomly assigned to different monitoring/heart-protection approaches to see what best helps keep the heart safe.
Nyack, New YorkAges 18 years+ - NCT05985655RecruitingPhase 1/Phase 2
Study of GTAEXS617 for advanced solid tumors
This trial tests a new drug called GTAEXS617 for adults with certain advanced solid tumors that have not responded to standard treatments. It aims to see if the drug is safe and effective.
New York, New YorkAges 18 years+ - NCT07085767RecruitingPhase 3
Palazestrant and ribociclib for first-line advanced breast cancer
This trial tests a new drug (palazestrant) combined with ribociclib for people with a common type of advanced breast cancer that is estrogen receptor-positive and HER2-negative. You may qualify if you haven't had treatment for advanced disease and your cancer has either just been found or came back long after completing hormone therapy.
New York, New YorkAges 18 years+ - NCT06518057RecruitingPhase 2
Sparing memory during brain radiation for leptomeningeal metastases
This trial tests a special type of radiation that avoids the memory center of the brain (the hippocampus) while treating cancer that has spread to the lining of the brain and spinal cord. It may help reduce side effects on thinking and memory for people with breast or lung cancer.
New York, New YorkAges 18 years+ - NCT04348747RecruitingPhase 2
Vaccine plus pembrolizumab for breast cancer in the brain
This trial studies whether a personalized immune-cell vaccine (dendritic cell vaccine) combined with pembrolizumab can help control brain metastases from certain types of breast cancer. It may help your immune system better recognize and attack cancer cells in the brain.
Buffalo, New YorkAges 18 years+ - NCT06500481RecruitingPhase 3
Proton vs standard radiation for cancer spread to brain/spine lining
This trial compares a newer type of radiation (proton therapy) to standard radiation for people whose breast or lung cancer has spread to the lining of the brain and spinal cord. It aims to see if proton therapy can better control the disease while causing fewer side effects.
New York, New YorkAges 18 years+ - NCT03448926Recruiting
DCIS test registry to guide radiation and drug decisions
This study collects information from people with breast ductal carcinoma in situ (DCIS) to see how a specific lab test (DCISionRT) may help predict who benefits from radiation and/or certain medications. Your results and clinical details are gathered during routine care, not necessarily to change treatment right away.
Brooklyn, New YorkAges 30–85 - NCT03897270Recruiting
Breast cancer or healthy women for new breast imaging
This study tests a new way to look at the breast using photoacoustic imaging, alongside a breast MRI. It may help researchers see breast masses more clearly, even though it’s mainly for measuring how well the imaging works.
Buffalo, New YorkAges 18 years+ - NCT07454642RecruitingPhase 1
Study of a new drug for advanced solid tumors
This trial tests a new drug called AVA6103 for people with certain advanced solid tumors that have not responded to standard treatments. The drug may help by targeting a protein on cancer cells and interfering with their ability to multiply.
New York, New YorkAges 18 years+ - NCT05877599RecruitingPhase 1
Study of a new treatment for advanced cancers with a specific gene change
This trial tests a new type of therapy (NT-175) for people with certain advanced cancers that have a specific genetic change. It might help if your tumor has the TP53 R175H mutation and you have the HLA-A*02:01 immune marker.
New York, New YorkAges 18 years+ - NCT06042569RecruitingPhase 2
Lower-dose chemo for older women with HER2-negative breast cancer
This trial tests whether a lower dose of two chemotherapy drugs (docetaxel and cyclophosphamide) works well for women 65 and older with early-stage HER2-negative breast cancer. The goal is to maintain effectiveness while reducing side effects in this group.
Rochester, New YorkAges 65 years+ - NCT06833255Recruiting
Support Program for Black Women Breast Cancer Survivors
This program pairs Black women who have completed breast cancer treatment with support to help them transition into survivorship. It offers mentorship based on how recently you finished treatment, with priority for those who had limited support or who identify as African American.
Buffalo, New YorkAges 18 years+ - NCT05929768RecruitingPhase 3
Shorter chemo plus immunotherapy without anthracyclines for early TNBC
This Phase 3 trial tests whether a shorter course of chemotherapy plus immunotherapy can work as well as standard treatment for early-stage triple-negative breast cancer. It avoids anthracycline drugs and may help reduce exposure to those medicines if the shorter plan is effective and safe.
Staten Island, New YorkAges 18 years+ - NCT04585750RecruitingPhase 1/Phase 2
Studying a new drug for cancers with a specific TP53 change
This trial tests a new drug (rezatapopt) for people with advanced cancers that have a specific change in the TP53 gene, called Y220C. The drug is designed to target this change and may slow or stop cancer growth. Some participants may also receive an immunotherapy drug called pembrolizumab (Keytruda).
New York, New YorkAges 12 years+ - NCT06084481RecruitingPhase 1
Study of a new drug for advanced solid tumors
This study tests a new intravenous drug called ABBV-400 in people with certain advanced solid tumors that have not responded to other treatments. The goal is to see if it can slow or stop tumor growth and to check for side effects.
New York, New YorkAges 18 years+ - NCT05787834Recruiting
Breathing exercises at home to reduce cancer treatment side effects
This study tests whether doing simple breathing exercises at home can help reduce side effects from cancer treatments like chemotherapy, immunotherapy, or radiation. It may help you feel better during your treatment.
Buffalo, New YorkAges 21 years+ - NCT05735080RecruitingPhase 1/Phase 2
INX-315 for advanced cancers with a specific gene change
This trial studies an experimental medicine (INX-315) given in an “open-label” way to people with advanced cancer that has not responded to prior treatment. It mainly looks at safety and side effects first, and also checks how well it works in cancers with a specific gene amplification.
Buffalo, New YorkAges 18 years+ - NCT06799065RecruitingPhase 1/Phase 2
Oral drug for advanced solid tumors including ovarian cancer
This trial tests a new daily pill that targets a protein helping cancer cells divide. It may stop tumors from growing in people with advanced or metastatic cancer that has returned or stopped responding to standard treatments, including some types of ovarian, lung, and other solid tumors.
Long Island City, New YorkAges 18 years+
Breast Carcinoma trials by city in New York
Where these studies are running in New York
Institutions with a site for the recruiting breast carcinoma studies listed above.
- Roswell Park Comprehensive Cancer Center · 7 studies
- Columbia University Irving Medical Center · 6 studies
- Memorial Sloan Kettering Cancer Center · 5 studies
- NYU Langone Health · 5 studies
- Stony Brook University Medical Center · 4 studies
- Glens Falls Hospital · 3 studies
- Montefiore Medical Center · 3 studies
- NYU Langone Hospital - Brooklyn · 3 studies
What taking part in a breast carcinoma study involves
A screening visit first
Before anything else, the study team checks whether you fit — usually a visit with some tests. You can stop at any point, and screening is typically free.
Care at a nearby site
Study visits happen at a clinic or hospital taking part. Many studies cover the cost of the study treatment and related visits, and some reimburse travel.
You stay in control
Taking part is voluntary and you can leave a study at any time, for any reason, without affecting your regular care.
The team decides eligibility
Our fit check is a helpful first read, not a decision. The study team makes the final call after reviewing your health history.
Breast Carcinoma trials in other states
Common questions
- Are there breast carcinoma clinical trials in New York?
- Yes. We're currently tracking 78 recruiting breast carcinoma studies with a site in New York, each rewritten in plain language so you can see what it's testing and who it's for.
- How do I find out if I qualify for a breast carcinoma study in New York?
- Each study lists its eligibility rules — age, diagnosis, prior treatments. On every trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Do I have to live in New York to take part?
- Not necessarily. These studies have a site in New York, but eligibility is about your health, not your address — some people travel to take part, and a few studies reimburse travel. The study team can tell you what's required.
- Does it cost anything to join a breast carcinoma trial?
- Using Clin2 is always free. Many trials cover the study treatment and related visits; some reimburse travel. The study team explains exactly what's covered before you decide.
Not the right time?
New breast carcinoma studies open in New York regularly. Set up a health profile and we’ll quietly watch for studies that fit you and email you when one opens.
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.